Comparative bioavailability of norfloxacin tablets based on blood and urine data

Medical Principles and Practice

Volumn 16, Issue 6, 2007, Pages 426-431

  Nada, Aly H ^a   Sharaf, Mohamed A ^b   El Gholmy, Zeinab A ^c   Khalafallah, Nawal M ^c  

^a KUWAIT UNIVERSITY   (Kuwait)

^b Alexandria Company for Pharmaceuticals   (Egypt)

^c Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Bioequivalence; Norfloxacin bioavailability; Noroxin

Indexed keywords

NORFLOXACIN;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NON INVASIVE MEASUREMENT; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; VALIDATION STUDY;

ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG COMPOUNDING; FEASIBILITY STUDIES; HUMANS; MALE; NORFLOXACIN; REFERENCE VALUES; TABLETS;

EID: 35148885170     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107746     Document Type: Article

References (14)

1. Carson C, Naber KG: Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections. Drugs 2004;64:1359-1373.
2. Sweetman SC (ed): Martindale, The Complete Drug Reference, ed 34. Pharmaceutical Press, London, 2004, p 239.
3. PDR Generics, ed 3. Medical Economics, Montvale, 1997.
4. Nada AH, Sharaf MA, Elgholmy ZA, Khalafallah NM: Effect of raw materials on the formulation of norfloxacin tablets. Pharm Technol Eur 2006; 18: 36-45.
5. The United States Pharmacopoeia, ed 25. United States Pharmacopeial Convention, Rochville, 2002, p 1250.
6. Pauliukonis LT, Musson DG, Bayne WF: Quantitation of norfloxacin, a new antibacterial agent in human plasma and urine by ion-pair reverse phase chromatography. J Pharm Sci 1984;73:99-102.
7. Johnston A, Woollard RC: STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods 1983;9:193-199.
8. Marzo A, Balant LP: Bioequivalence. Updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneimittelforschung 1995;45:109-115.
9. Barre J, Houin G, Tillement JP: Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans. J Pharm Sci 1984;73:1379-1382.
10. Swanson BN, Boppana VK, Vlasses PH, Rotmensch HH, Ferguson RK: Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 1983;23:284-288.
11. Adhami ZN, Wise R, Weston D, Crump B: The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother 1984;13:87-92.
12. Wise R, Lister D, McNulty CA, Griggs D, Andrews JM: The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. Infection 1986;14:S196-S202.
13. Lee SF, Wang RB, Lin MF: Comparative bioavailability and pharmacokinetics of norfloxacin. Zhonghua Yaoxue Zazhi 1992;44:413-420.
14. Chen X, Liu X, Huang S, Wang F: Pharmacokinetics of norfloxacin by constant rate infusion. Zhongguo Linchuang Yaoli Zazhi 1992;8:82-86.